Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents

Younghoon Kee1, Min Huang, Sophia Chang

  • 1Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, Florida, USA. Ykee@usf.edu

Insights

Inhibiting the Nedd8 conjugation system enhances cancer cell sensitivity to DNA interstrand cross-link (ICL) agents by suppressing the Fanconi anemia pathway. This suggests combining Nedd8 inhibitors with ICL drugs could overcome drug resistance.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • DNA Repair

Background:

  • The Fanconi anemia (FA) pathway is crucial for repairing DNA interstrand cross-links (ICLs).
  • FA pathway deficiency increases sensitivity to ICL-inducing drugs like cisplatin.
  • Hyperactivation of the FA pathway can lead to cellular resistance to ICL agents.

Purpose of the Study:

  • To investigate the effect of inhibiting the Nedd8 conjugation system on cellular sensitivity to DNA ICL-inducing agents.
  • To explore the underlying mechanisms by which Nedd8 inhibition impacts the Fanconi anemia pathway and DNA damage response.

Main Methods:

  • Utilized siRNA-mediated knockdown of Nedd8-conjugating enzymes.
  • Administered MLN4924, a Nedd8-activating enzyme inhibitor.
  • Assessed DNA damage-induced FANCD2 monoubiquitination and CHK1 phosphorylation.

Main Results:

  • Nedd8 inhibition significantly increased cellular sensitivity to DNA ICL-inducing agents.
  • Suppression of DNA damage-induced FANCD2 monoubiquitination and CHK1 phosphorylation was observed upon Nedd8 inhibition.
  • The heightened sensitivity to ICLs was primarily attributed to the inhibition of the Fanconi anemia pathway.

Conclusions:

  • Inhibition of the Nedd8 conjugation system effectively sensitizes cells to DNA ICL-inducing agents.
  • Targeting the Nedd8 conjugation system disrupts the Fanconi anemia pathway, a key DNA repair mechanism.
  • Combining Nedd8 inhibition with ICL agents presents a potential therapeutic strategy to overcome drug resistance in certain cancer cells.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Nucleotide Excision Repair01:38

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...